within Pharmacolibrary.Drugs.ATC.M;

model M01AH01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 27.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.455,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Celecoxib is a selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and acute pain. It is an approved prescription medication in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after a single oral dose administration.</p><h4>References</h4><ol><li><p>Pal, A, et al., &amp; Gobburru, J (2017). Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. <i>Clinical drug investigation</i> 37(10) 937–946. DOI:<a href=&quot;https://doi.org/10.1007/s40261-017-0548-6&quot;>10.1007/s40261-017-0548-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28748412/&quot;>https://pubmed.ncbi.nlm.nih.gov/28748412</a></p></li><li><p>Silberstein, S, et al., &amp; Kunkel, T (2023). Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review. <i>Pain and therapy</i> 12(5) 1109–1119. DOI:<a href=&quot;https://doi.org/10.1007/s40122-023-00529-7&quot;>10.1007/s40122-023-00529-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37329440/&quot;>https://pubmed.ncbi.nlm.nih.gov/37329440</a></p></li><li><p>Paulson, SK, et al., &amp; Karim, A (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. <i>The Journal of pharmacology and experimental therapeutics</i> 297(2) 638–645. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11303053/&quot;>https://pubmed.ncbi.nlm.nih.gov/11303053</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AH01;
